Regulatory compliance - June 30, 2013
EU fines drug firms for delaying generics
The EU commission has filed Danish Lundbeck and eight other pharmaceutical firms for paying off rivals to delay production of generics. Photo. European Commissioner for Competition Joaquin Almunia during a press conference. The EU commission reached a decision in the several years’ long trial on Danish pharmaceutical firm Lundbeck for blocking generic versions of antidepressant drug […]
Collaboration - June 27, 2013
AstraZeneca in new collaborations
AstraZeneca join forces with Roche to share early data trial and teams up with Karolinska Institute for an integrated centre for cardiovascular and metabolic diseases. On June 26, AstraZeneca and Roche announced that the companies have entered a new collaboration to share a specific type of early research data related to drug design. The aim […]
Biotech Business - June 27, 2013
Creative Antibiotics files for bankruptcy
The Swedish antibiotics company cancels its reconstruction and is now filing for bankruptcy. Creative Antibiotics CEO Ulf Boberg. The company had initiated a reconstruction on June 3. Creative Antibiotics is noted on Aktietorget and was removed from the list on June 25. The company has been through a period of instability. They managed to evade […]
Imaging - June 25, 2013
Seeing is believing
Previously scientists looked at everything at the same time, resulting in a blurry image. With the optical tricks and recent developments in microscopy, scientists can now obtain super-resolution images of objects and discover worlds which they have never seen before. The digital developments within imaging have resulted in dramatic changes over the past decades. From […]
Clinical Trials - June 25, 2013
Turning the spotlight on patients
Involving patients earlier in the development of new treatments and drugs is becoming a more highlighted issue. Recent survey findings and reports show that Swedish patients are more likely to experience problems due to inadequate coordination of their care than patients in many other countries , and that Swedish patients are among the least engaged […]
Agreement - June 17, 2013
Neurovive and Isomerase enter agreement
Mitochondrial medicine company Neurovive Pharmaceutical recently announced the signing of a collaboration agreement with Isomerase Therapeutics. The agreement involves the product development and commercialization of the cyclophilin-inhibiting molecules that were recently acquired from Biotica Ltd. According to a press release, the collaboration will focus on cellular protection for traumatic brain injury and heart attack, and […]
